Recce Pharmaceuticals Ltd (ASX:RCE, OTC:RECEF) is continuing its vital anti-infective work from the company’s Anti-Infective Research (AIR) unit at the Murdoch Children’s Research Institute (MCRI).
Innovative partnership
The partnership is testament to the commitment of both organisations to drive innovation in the field of anti-infective therapeutics.
In 2023 Recce established the dedicated AIR Unit, which is led by MCRI researcher Dr Sohinee Sarkar, and leverages MCRI’s state-of-the-art research facilities and expertise.
With MCRI’s world-class medical resources, Recce has the capability to streamline its ongoing pre-clinical programs while investigating new indications for future clinical trials.
The collaboration between Recce and MCRI has been key to providing promising results in ongoing pre-clinical programs, including the delivery of positive efficacy data from RECCE® 327’s pre-clinical programs against a broad range of life-threatening infectious pathogens.
Killer pathogens
Recce is targeting killers such as Escherichia coli – which can lead to UTIs and urosepsis – Mycobacterium abscessus, Streptococcus pneumoniae and Neisseria gonorrhoeae, the last of which is a priority pathogen on the World Health Organization’s list of bacteria that pose the greatest threat to human health.
“The threat of antibiotic resistance is greater now than ever, and commercial-academic partnerships are crucial to advance antibiotic discovery,” said MCRI theme director – Infection, Immunity and Global Health Prof Andrew Steer.
“The partnership between Recce and MCRI will advance efforts and promote Australian leadership in the fight against antibiotic resistance.”
The collaboration between Recce’s AIR Unit and MCRI demonstrates the power of partnership in driving medical breakthroughs.
Global health threat
Both organisations are committed to the shared project of advancing anti-infective research to address what is rapidly becoming the global health challenge of our time – anti-microbial resistance.
Recce CEO James Graham said: “Our continued work at the AIR Unit aligns with Murdoch Children’s mission to address the global health threat of anti-microbial resistance through innovative research.
“The synergy between our organisations will undoubtedly lead to ground-breaking discoveries that have the potential to transform the landscape of infectious disease treatment."